Alec Reynolds

Alec joined Flagship Pioneering in 2020 and is responsible for building the operations model and portfolio strategy for Pioneering Medicines with a focus on delivering innovative therapies for patients.

He has years of global industry expertise in shaping and executing asset strategies, focusing capital on the highest value programs, and strengthening critical organization capabilities to drive programs. He is a proven leader with a strong understanding of operational, clinical, and regulatory requirements as well as business and financial management skills.

Prior to joining Flagship, Alec spent more than 12 years at Celgene in senior roles including Corporate Vice President of the Global Project Leadership team responsible for more than 20 late-stage development projects in hematology-oncology and inflammation-immunology, including six NDA and BLA’s which advanced toward submission within a year. Alec was a key figure in Celgene’s growth and was a member of the company’s Development Committee. He previously served as the global project leader for Revlimid in Multiple Myeloma, the company’s $10 billion flagship therapy and helped achieve several key regulatory approvals. Alec was on the founding leadership team of Celgene China and lived in Shanghai for three years building that business. Prior to Celgene, Alec worked at the U.S. Treasury, The Carlyle Group, and Morgan Stanley.

Alec received his M.B.A. from the University of Virginia Darden Graduate School of Business and his A.B. in Politics from Princeton University.